A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin

Pediatr Dermatol. 2005 Jul-Aug;22(4):317-20. doi: 10.1111/j.1525-1470.2005.22407.x.

Abstract

Toxic epidermal necrolysis and Stevens-Johnson syndrome are severe skin reactions, usually to drugs, associated with a widespread destruction of the epidermis. Widespread purpuric macules and epidermal detachment of less than 10% of the body surface is indicative of Stevens-Johnson syndrome, whereas epidermal detachment between 10% and 30% is called Stevens-Johnson-toxic epidermal necrolysis overlap. Epidermal detachment involving more than 30% of the total body surface is designated as toxic epidermal necrolysis. These generalized reactions are known to occur in association with various drugs. Treatment is primarily supportive care, and there are no specific therapy regimens. Therapeutic modalities such as corticosteroids, cyclosporin, thalidomide, cyclophosphamide, and plasmapheresis, usually based on a symptomatic approach, have been tried in single patients or in small series. Intravenous immunoglobulin has recently been shown to provide rapid improvement in all three of these skin reactions. We report a 2-year-old girl who developed Stevens-Johnson syndrome-toxic epidermal necrolysis overlap after receiving ampicillin-sulbactam for an upper respiratory tract infection. She was treated successfully with a 4-day course of intravenous immunoglobulin.

Publication types

  • Case Reports

MeSH terms

  • Ampicillin / adverse effects
  • Anti-Bacterial Agents / adverse effects
  • Child, Preschool
  • Female
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Respiratory Tract Infections / drug therapy
  • Stevens-Johnson Syndrome / complications
  • Stevens-Johnson Syndrome / drug therapy*
  • Stevens-Johnson Syndrome / etiology
  • Sulbactam / adverse effects

Substances

  • Anti-Bacterial Agents
  • Immunoglobulins, Intravenous
  • Ampicillin
  • Sulbactam